Australia markets closed

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
63.08-1.03 (-1.61%)
As of 12:01PM EST. Market open.

Vir Biotechnology, Inc.

499 Illinois Street
Suite 500
San Francisco, CA 94158
United States
415 906 4324

Full-time employees297

Key executives

NameTitlePayExercisedYear born
Dr. George A. ScangosPres, CEO & Director785.83kN/A1948
Dr. Klaus FruehCo-Founder & Scientific Advisor177.66kN/A1960
Mr. Howard HornCFO & Sec.599.25kN/A1977
Dr. Herbert W. Virgin IVExec. VP of Research & Chief Scientific Officer949.9kN/A1956
Dr. Jay ParrishCo-Founder & Chief Bus. OfficerN/AN/A1975
Dr. Lawrence CoreyCo-Founder & Scientific AdvisorN/AN/AN/A
Dr. Louis J. PickerCo-Founder & Scientific AdvisorN/AN/AN/A
Dr. Michael E. KamarckChief Technology OfficerN/AN/A1951
Mr. Steven J. RiceChief Admin. OfficerN/AN/AN/A
Dr. Neera Dahiya Ravindran M.D., MBAVP and Head of Investor Relations & Strategic CommunicationsN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

Corporate governance

Vir Biotechnology, Inc.’s ISS governance QualityScore as of 2 December 2020 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.